Daily Aspirin Cuts Odds for Colon Cancer: Who Benefits Most?
By Ernie Mundell HealthDay Reporter
THURSDAY, Aug. 1, 2024 -- It's long been known that a daily dose of low-dose aspirin helps keep colon cancer at bay.
But new research suggests that those who benefit most are folks whose lifestyles up their odds for the disease in the first place.
“Our results show that aspirin can proportionally lower the markedly elevated risk in those with multiple risk factors for colorectal cancer,” said study lead author Dr. Daniel Sikavi. He's a gastroenterologist at Massachusetts General Hospital (MGH) in Boston.
Aspirin is thought to prevent colon cancer by lowering the production of pro-inflammatory proteins, known as prostaglandins, that can spur tumor development.
But there may be other factors at play, and "aspirin likely prevents colorectal cancer through multiple mechanisms," according to study co-senior author Dr. Andrew Chan, director of epidemiology for the Mass General Cancer Center.
However, the story of daily aspirin's role in colon cancer prevention has been a rocky one.
The U.S. Preventive Services Task Force, an influential and independent panel of experts, at first recommended low-dose (81 milligrams) aspirin on a daily basis as a means of preventing both heart disease and colon cancer, based on a wide array of data. However, the task force rescinded that guidance in 2016, saying that the risk of bleeding from long-term aspirin use negated any other health benefit.
But might daily aspirin benefit some users more than others?
To find out, Sikavi's group looked at data from almost 108,000 participants from the Nurses’ Health Study and Health Professionals Follow-Up Study.
People averaged just over 49 years of age when they entered the study, and the researchers compared colon cancer rates among those who took aspirin regularly with those who did not.
Regular aspirin use was defined as taking either two or more standard dose (325 mg) tablets per week or a daily low-dose aspirin.
The result: Over 10 years, nearly 2% of regular aspirin users developed colon cancer, compared to nearly 3% of those who didn't take the drug, a significant difference.
When ranked by healthy/unhealthy lifestyles, even bigger differences emerged.
Among the group of participants deemed to have the most unhealthy risk factors, 2.12% of regular aspirin users developed colon cancer, compared to 3.4 percent of those who didn't take aspirin, the study found.
In contrast, no such difference was seen among folks deemed to have the healthiest lifestyles. If they popped aspirin regularly, their colon cancer incidence was 1.5 percent; if they did not, it was 1.6%, the researchers found.
Put another way, in the least healthy group it would take treating 78 people with daily aspirin to prevent one case of colon cancer; among the healthiest cohort that number rose to 909.
That makes sense, Sikari said, since "those with a healthier lifestyle have a lower baseline risk of colorectal cancer, and, therefore, their benefit from aspirin was still evident, albeit less pronounced.”
The researchers noted that their study did not track rates of aspirin's leading side effect, bleeding.
The findings were published Aug. 1 in the journal JAMA Oncology.
So, what might all this mean for average Americans worried about colon cancer?
"Healthcare providers might more strongly consider recommending aspirin to patients who have less healthy lifestyles,” reasoned study co-senior author Dr. Long Nguyen. He's a physician investigator in the Clinical and Translational Epidemiology Unit and Division of Gastroenterology at MGH.
If a person chooses to regularly take aspirin, Nguyen said that "based on prior studies, the best evidence supports daily low-dose [81 mg] aspirin for prevention," rather than weekly doses of 325 mg of aspirin.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-02 01:15
Read more
- Pandemic-Linked Worldwide Declines in Childhood Vaccination Not Yet Recovered
- FDA Approves Vyloy (zolbetuximab-clzb) for the Treatment of Advanced Gastric and GEJ Cancer
- Infectious Diseases Society of America, Oct. 16-19
- People's Brains Now Process Texts Almost as Quickly as Pictures
- Vasomotor Symptoms During Menopause May Up Risk for Type 2 Diabetes
- ACAAI: Most Syphilis Patients With Penicillin Allergy Have Low Risk for Severe Allergy
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions